Your browser doesn't support javascript.
loading
A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America.
Rossi, Benedito Mauro; Palmero, Edenir Inêz; López-Kostner, Francisco; Sarroca, Carlos; Vaccaro, Carlos Alberto; Spirandelli, Florencia; Ashton-Prolla, Patricia; Rodriguez, Yenni; de Campos Reis Galvão, Henrique; Reis, Rui Manuel; Escremim de Paula, André; Capochin Romagnolo, Luis Gustavo; Alvarez, Karin; Della Valle, Adriana; Neffa, Florencia; Kalfayan, Pablo German; Spirandelli, Enrique; Chialina, Sergio; Gutiérrez Angulo, Melva; Castro-Mujica, Maria Del Carmen; Sanchez de Monte, Julio; Quispe, Richard; da Silva, Sabrina Daniela; Rossi, Norma Teresa; Barletta-Carrillo, Claudia; Revollo, Susana; Taborga, Ximena; Morillas, L Lena; Tubeuf, Hélène; Monteiro-Santos, Erika Maria; Piñero, Tamara Alejandra; Dominguez-Barrera, Constantino; Wernhoff, Patrik; Martins, Alexandra; Hovig, Eivind; Møller, Pål; Dominguez-Valentin, Mev.
Afiliación
  • Rossi BM; Hospital Sirio Libanes, Sao Paulo, Brazil.
  • Palmero EI; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil.
  • López-Kostner F; Laboratorio de Oncología y Genética Molecular, Clínica Los Condes, Santiago, Chile.
  • Sarroca C; Hospital Fuerzas Armadas, Grupo Colaborativo Uruguayo, Investigación de Afecciones Oncológicas Hereditarias (GCU), Montevideo, Uruguay.
  • Vaccaro CA; Hereditary Cancer Program (PROCANHE), Hospital Italiano, Buenos Aires, Argentina.
  • Spirandelli F; Servicio de Coloproctologia y Asesoria Genetica en Cancer, Hospital Español de Rosario, Rosario, Argentina.
  • Ashton-Prolla P; Departamento de Genética da Universidade Federal do Rio Grande do Sul (UFRGS) e Serviço de Genética Médica do Hospital de Clinicas de Porto Alegre (HCPA) & Rede Brasileira de Câncer Hereditário, Porto Alegre, Rio Grande Do Sul, Brazil.
  • Rodriguez Y; Clinica del Country, Bogota, Colombia.
  • de Campos Reis Galvão H; Oncogenetics Department, Barretos Cancer Hospital, Barretos, SP, Brazil.
  • Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital & Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal.
  • Escremim de Paula A; ICVS/3B's-PT Government Associate Laboratory, Braga, Guimarães, Portugal.
  • Capochin Romagnolo LG; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil.
  • Alvarez K; Oncogenetics Department, Barretos Cancer Hospital, Barretos, SP, Brazil.
  • Della Valle A; Laboratorio de Oncología y Genética Molecular, Clínica Los Condes, Santiago, Chile.
  • Neffa F; Hospital Fuerzas Armadas, Grupo Colaborativo Uruguayo, Investigación de Afecciones Oncológicas Hereditarias (GCU), Montevideo, Uruguay.
  • Kalfayan PG; Hospital Fuerzas Armadas, Grupo Colaborativo Uruguayo, Investigación de Afecciones Oncológicas Hereditarias (GCU), Montevideo, Uruguay.
  • Spirandelli E; Hereditary Cancer Program (PROCANHE), Hospital Italiano, Buenos Aires, Argentina.
  • Chialina S; Servicio de Coloproctologia y Asesoria Genetica en Cancer, Hospital Español de Rosario, Rosario, Argentina.
  • Gutiérrez Angulo M; Servicio de Coloproctologia y Asesoria Genetica en Cancer, Hospital Español de Rosario, Rosario, Argentina.
  • Castro-Mujica MDC; Centro Universitario de los Altos, Universidad de Guadalajara, Jalisco, Mexico.
  • Sanchez de Monte J; Equipo Funcional de Genética y Biologia Molecular, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Quispe R; Instituto Nacional de Cancerologia de México, México City, Mexico.
  • da Silva SD; Laboratorio de Genética Molecular del Instituto de Servicios de Laboratorio de Diagnóstico e Investigación en Salud (SELADIS), La Paz, Bolivia.
  • Rossi NT; Lady Davis Institute for Medical Research and Segal Cancer Center, Jewish General Hospital, Montreal, Quebec, Canada.
  • Barletta-Carrillo C; Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Quebec, Canada.
  • Revollo S; Hospital Privado Universitario de Cordoba, Cordoba, Argentina.
  • Taborga X; Equipo Funcional de Genética y Biologia Molecular, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
  • Morillas LL; Laboratorio de Genética Molecular del Instituto de Servicios de Laboratorio de Diagnóstico e Investigación en Salud (SELADIS), La Paz, Bolivia.
  • Tubeuf H; Laboratorio de Genética Molecular del Instituto de Servicios de Laboratorio de Diagnóstico e Investigación en Salud (SELADIS), La Paz, Bolivia.
  • Monteiro-Santos EM; Centro de Enfermedades Neoplasicas ONCOVIDA, La Paz, Bolivia.
  • Piñero TA; Inserm-U1079-IRIB, UNIROUEN, Normandie Univ, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
  • Dominguez-Barrera C; Interactive Biosoftware, Rouen, France.
  • Wernhoff P; Hospital Sirio Libanes, Sao Paulo, Brazil.
  • Martins A; Instituto de Ciencias Basicas y Medicina Experimental (ICBME), Hospital Italiano, Buenos Aires, Argentina.
  • Hovig E; Department of Preventive Medicine, Faculty of Medicine, Universidad Nacional Mayor de San Marcos (UNMSM), Lima, Peru.
  • Møller P; Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway.
  • Dominguez-Valentin M; Inserm-U1079-IRIB, UNIROUEN, Normandie Univ, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.
BMC Cancer ; 17(1): 623, 2017 Sep 05.
Article en En | MEDLINE | ID: mdl-28874130
ABSTRACT

BACKGROUND:

Genetic counselling and testing for Lynch syndrome (LS) have recently been introduced in several Latin America countries. We aimed to characterize the clinical, molecular and mismatch repair (MMR) variants spectrum of patients with suspected LS in Latin America.

METHODS:

Eleven LS hereditary cancer registries and 34 published LS databases were used to identify unrelated families that fulfilled the Amsterdam II (AMSII) criteria and/or the Bethesda guidelines or suggestive of a dominant colorectal (CRC) inheritance syndrome.

RESULTS:

We performed a thorough investigation of 15 countries and identified 6 countries where germline genetic testing for LS is available and 3 countries where tumor testing is used in the LS diagnosis. The spectrum of pathogenic MMR variants included MLH1 up to 54%, MSH2 up to 43%, MSH6 up to 10%, PMS2 up to 3% and EPCAM up to 0.8%. The Latin America MMR spectrum is broad with a total of 220 different variants which 80% were private and 20% were recurrent. Frequent regions included exons 11 of MLH1 (15%), exon 3 and 7 of MSH2 (17 and 15%, respectively), exon 4 of MSH6 (65%), exons 11 and 13 of PMS2 (31% and 23%, respectively). Sixteen international founder variants in MLH1, MSH2 and MSH6 were identified and 41 (19%) variants have not previously been reported, thus representing novel genetic variants in the MMR genes. The AMSII criteria was the most used clinical criteria to identify pathogenic MMR carriers although microsatellite instability, immunohistochemistry and family history are still the primary methods in several countries where no genetic testing for LS is available yet.

CONCLUSION:

The Latin America LS pathogenic MMR variants spectrum included new variants, frequently altered genetic regions and potential founder effects, emphasizing the relevance implementing Lynch syndrome genetic testing and counseling in all of Latin America countries.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales Hereditarias sin Poliposis Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales Hereditarias sin Poliposis Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM